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USPHS and IDSA Collaborate on
Guidelines to Prevent Opportunistic
Infections in HIV-Infected Persons
U.S. Public Health Service (USPHS)/Infectious
Diseases Society of America (IDSA) Guidelines for
Preventing Opportunistic Infections in HIV-Infected
Persons will be published in an August 1995 supple-
ment of Clinical Infectious Diseases. The guidelines,
which are intended for health care providers, are the
result of collaboration between the Centers for Dis-
ease Control and Prevention (CDC), the National
Institutes of Health, IDSA, numerous federal and
nonfederal organizations, community groups, and
HIV-infected persons. The guidelines are endorsed
by the American Academy of Pediatrics, the Infec-
tious Diseases Society of Obstetrics and Gynecology,
and the Society of Healthcare Epidemiologists of
America. Jonathan E. Kaplan, M.D. (CDC), Henry
Masur, M.D. (NIH), and King Holmes, M.D., Ph.D.
(University of Washington), chaired the
USPHS/IDSA Prevention of Opportunistic Infec-
tions Working Group and are guest editors of the
Clinical Infectious Diseases supplement.
CDC initiated work on the guidelines in early
1994; meetings were held in Atlanta in June and
September to discuss and refine the recommenda-
tions.
The USPHS/IDSA guidelines address 17 oppor-
tunistic infections from three angles: 1) preventing
exposure to opportunistic pathogens (e.g., sexual,
occupational, and environmental exposure as well
as exposure through pets, food, water, and interna-
tional travel); 2) preventing opportunistic disease by
chemoprophylaxis and vaccination; and 3) prevent-
ing disease recurrence. In this document, new rec-
ommendations were made and earlier recommenda-
tions were updated. For example, new guidelines
recommend that in nonemergency situations, cyto-
megalovirus (CMV)-seronegative HIV-infected per-
sons who require blood transfusions receive only
Japanese Encephalitis Acquired
in Australia
Japanese encephalitis (JE), a mosquito-borne
flaviviral disease of humans and animals, is a major
public health problem in Asia, where an estimated
50,000 cases occur each year. There has been concern
that the range of epidemic JE may be expanding.
On April 5, 1995, an outbreak of three cases of JE
was recognized in Australia. Two of the cases were
fatal; all were among residents of an island in Aus-
tralia’s Torres Strait, which lies between mainland
Queensland and Papua New Guinea. JE was con-
firmed in two of the patients by polymerase chain
reaction (Jeffrey Hanna, Queensland Health, pers.
comm.). No other cases were reported. This is the
first recognized episode of JE acquired in Australia.
Control activities on the Australian island began
on April 7. The community was informed about the
importance of personal mosquito protection meas-
ures. In addition, larvicides were applied, and areas
were fogged to kill adult mosquitoes.
The patients were all male, aged 6 to 44 years. All
were hospitalized with symptoms that included fe-
ver (up to 40oC), stiff or painful neck, headache, and
abdominal pain. Two patients were unconscious at
the time of admission.
Acute-phase sera showed elevated JE virus im-
munoglobulin M (IgM) titers. Two of the patients
also had detectable levels of Kunjin and Murray
Valley encephalitis virus IgM, but the JE IgM titers
were significantly higher in each case.
Flaviviruses have also been isolated from the
sera of each of two asymptomatic island residents.
Preliminary tests suggest that these are both JE
virus. Blood taken from 10 horses and 12 domestic
pigs living near humans on the island was also
tested. All 12 pigs and 9 of the horses had high JE
titers by hemagglutination inhibition assay. Neu-
tralizing antibody to JE virus was detectable in all
the pigs and in four of the horses tested to date.
Details of the index case are as follows: The
patient, a 16-year-old male, was admitted to Thurs-
day Island Hospital on March 22, 1995. He was
unconscious and was responsive only to painful
stimuli. His neck was stiff, and he showed a prefer-
ence for moving his right side. His illness had begun
3 days before. The day before admission he com-
plained of abdominal pain. This patient had been
mildly mentally retarded since birth and occasionally
had generalized seizures but was generally healthy.
He was transferred to Cairns Base Hospital, where a
cerebral CT scan showed a nonenhancing hypodense
lesion in his posterior right basal ganglia.
He had a leukocytosis of 17.3 ´ 109L, neutrophils,
15.2  ´ 109. His cerebrospinal fluid contained 150
leukocytes/ml with a differential count of 50% poly-
morphs and 50% mononuclear cells.
He had a generalized seizure and 2 days after
admission, required mechanical ventilation. He
never regained consciousness and died on day 17 of
hospitalization (April 8).
Adapted from Hanna J, Ritchie S, Loewenthal M,
et al. Probable Japanese encephalitis acquired in
the Torres Strait. Communicable Diseases Intelli-
gence 1995;19:206-7.
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lar blood products. The guidelines also recommend
that Toxoplasma-seropositive HIV-infected persons
who have a CD4+ lymphocyte count <100 cells/mL
received chemoprophylaxis against toxoplasmosis
(such chemoprophylaxis is generally accomplished
with anti-Pneumocystis carinii medication). Earlier
recommendations for chemoprophylaxis against
Pneumocystis carinii pneumonia and Mycobac-
terium avium complex disease have also been up-
dated.
In addition to disease-specific recommendations,
the guidelines include an overview article designed
to prioritize the recommendations for health care
providers. This article provides an approach to the
initial and follow-up evaluations of the HIV-infected
patient and also contains sections on HIV-infected
pregnant women and HIV-exposed/infected chil-
dren. The guidelines are followed by 15 background
articles, which provide the information on which the
recommendations were based and include research
priorities generated by the development of the pre-
vention recommendations.
The guidelines conclude with quality standards
and implementation steps on the most standard-of-
care recommendations, such as chemoprophylaxis
against Pneumocystis carinii pneumonia. This final
section provides a mechanism by which health care
facilities can assess their degree of compliance with
the recommendations, so that they can detect and
correct compliance-related problems.
 An abbreviated version of the USPHS/IDSA
Guidelines will be published in CDC’s Morbidity and
Mortality Weekly Report in July.
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Recommendations for a Regional
Strategy for the Prevention and
Control of Emerging Infectious
Diseases in the Americas
On June 14-15, 1995, a conference on “Combating
Emerging Infectious diseases: Challenges for the
Americas” was held at the Pan American Health
Organization (PAHO) Headquarters in Washington,
D.C. The meeting was designed to shape a regional
strategy for preventing and controlling emerging
infectious diseases that could pose serious threats
to the peoples of the Americas.
Participants, convened by PAHO, included top offi-
cials and infectious disease experts from that organi-
zation as well as the World Health Organization, the
U.S. Centers for Disease Control and Prevention, the
Canadian Laboratory Center for Disease Control, the
U.S. Department of Defense, and several Latin Ameri-
can and Caribbean countries.
This international group of experts noted that an
increasing number of new, emerging, and ree-
merging infectious diseases have been identified in
both developed and developing nations and that
these diseases threaten to increase in the near fu-
ture. They include human immunodeficiency vi-
rus/acquired immunodeficiency syndrome, which
emerged in the l980s and now affects some 16 mil-
lion people worldwide; and cholera, which returned
to the Western Hemisphere for the first time this
century in 1991 and has caused more than 1 million
cases and 9,000 deaths in the Americas. PAHO esti-
mates that it will take more than a decade and over
$200 billion to control the current pandemic of this
disease.
The experts concluded that both early warnings
of, and rapid responses to, infectious disease threats
are needed. The group made several major recom-
mendations to PAHO and its member states to im-
prove surveillance, research, and communications
in developing countries. They also issued more de-
tailed recommendations in the areas of antimicro-
bial resistance, outbreak control, and information
and communication. In addition, a plan of action is
forthcoming.
The group made the following recommendations
for PAHO and its member countries:
General Recommendations
· Develop and frequently update prioritized dis-
ease-specific guidelines for the prevention and
control of diseases that are emerging or ree-
merging, both at the public health and individual
levels. This should include biologic and behav-
ioral change measures and will require groups of
experts for each disease as well as communica-
tions experts. Diseases of interest include yellow
fever, dengue, antimicrobial-resistant organisms
(malaria, tuberculosis, and enteric diseases),
measles, polio, cholera and other foodborne and
waterborne diseases, viral hemorrhagic fevers,
plague, rabies and other zoonoses, and try-
panosomiasis and other vector-borne diseases.
· Identify points of contact in the field to receive
and transmit information in countries. These
contacts should include organizations and indi-
viduals outside the government.
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